Explore the frontier of life sciences and healthcare innovation. From breakthrough therapeutics and longevity research to the deep tech investments shaping tomorrow's treatments, discover the trends and breakthroughs redefining global health.
Faro AI raised a $37.3M Series B, co-led by Merck Global Health Innovation Fund and S32, to put AI agents inside clinical development workflows. Six of the world's ten largest pharma companies already use the platform.
Anthropic's $400 million acquisition of Coefficient Bio marks a new class of biotech buyer: frontier AI labs paying for models and talent instead of clinical assets. Here is the exit math, the risk, and what it means for founders and investors.
Windfall Bio was one of the best-funded bets on turning methane into fertilizer. It scaled production, passed field trials, then ran out of runway. The collapse says less about methane-eating microbes than about the cost of the machines around them.
An oversubscribed Series A and an FDA green light arrived the same morning. TwoStep's peptide-drug conjugate is a bet that reach beats a perfect target in solid-tumor oncology.
Typewriter emerged from stealth with a $56M Series A to commercialize retrotransposon-based whole-gene insertion, targeting in vivo CAR-T and genetic liver disease. Non-human primate data arrives late 2026.
RASONQUE (daraxonrasib) is the first approved drug to hit RAS directly, the driver behind 90% of pancreatic tumours. In RASolute 302 it doubled median survival. Then came the $39,800-a-month list price. We assess the clinical event against the commercial bet.
Cell-free biomanufacturing crossed from lab to industrial pilot in 18 months. Four companies carry the commercial thesis.
Generate:Biomedicines has moved its AI-engineered anti-TSLP antibody GB-0895 into two global Phase 3 trials in severe asthma. 1,600 patients, six-month dosing, $457.4M in cash. The readout will revalue the entire generative-biology cohort.